KR20230005962A - 베타코로나바이러스 예방 및 치료요법 - Google Patents

베타코로나바이러스 예방 및 치료요법 Download PDF

Info

Publication number
KR20230005962A
KR20230005962A KR1020227042131A KR20227042131A KR20230005962A KR 20230005962 A KR20230005962 A KR 20230005962A KR 1020227042131 A KR1020227042131 A KR 1020227042131A KR 20227042131 A KR20227042131 A KR 20227042131A KR 20230005962 A KR20230005962 A KR 20230005962A
Authority
KR
South Korea
Prior art keywords
seq
vaccine
unit
epitope
betacoronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227042131A
Other languages
English (en)
Korean (ko)
Inventor
아그네테 브룬스빅 프레드릭센
모니카 세켈리아
카롤리네 쉬예트네
군슈타인 노르하임
엘리자베스 슈툽스루드
Original Assignee
니코데 테라퓨틱스 에이에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니코데 테라퓨틱스 에이에스에이 filed Critical 니코데 테라퓨틱스 에이에스에이
Publication of KR20230005962A publication Critical patent/KR20230005962A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6056Antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227042131A 2020-05-01 2021-05-03 베타코로나바이러스 예방 및 치료요법 Pending KR20230005962A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DKPA202070282 2020-05-01
DKPA202070282 2020-05-01
DKPA202070293 2020-05-06
DKPA202070293 2020-05-06
DKPA202070735 2020-11-05
DKPA202070735 2020-11-05
DKPA202070820 2020-12-08
DKPA202070820 2020-12-08
DKPA202170069 2021-02-15
DKPA202170069 2021-02-15
PCT/EP2021/061602 WO2021219897A1 (en) 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy

Publications (1)

Publication Number Publication Date
KR20230005962A true KR20230005962A (ko) 2023-01-10

Family

ID=75870604

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042131A Pending KR20230005962A (ko) 2020-05-01 2021-05-03 베타코로나바이러스 예방 및 치료요법

Country Status (11)

Country Link
US (1) US20230165952A1 (https=)
EP (1) EP4143210A1 (https=)
JP (1) JP2023524054A (https=)
KR (1) KR20230005962A (https=)
CN (1) CN116096735A (https=)
AU (1) AU2021262521A1 (https=)
BR (1) BR112022021905A2 (https=)
CA (1) CA3176527A1 (https=)
IL (1) IL297621A (https=)
MX (1) MX2022013661A (https=)
WO (1) WO2021219897A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
CN112028978B (zh) * 2020-09-07 2023-06-16 重庆医科大学 新冠病毒特异性cd8+t细胞表位肽及其应用
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
JP2024518463A (ja) 2021-05-10 2024-05-01 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 構築物及び免疫阻害化合物の共発現
TW202334429A (zh) * 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
CN114832099B (zh) * 2022-04-08 2023-11-28 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
US20260007729A1 (en) * 2022-08-17 2026-01-08 IMMUNEO Therapeutics GmbH Immunization against viral infections disease(s)
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
LU102995B1 (en) * 2022-08-17 2024-02-19 PMCR GmbH Immunization against coronavirus
WO2024044747A2 (en) * 2022-08-25 2024-02-29 University Of Florida Research Foundation, Inc. Immunogenic composition and uses thereof
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024155907A2 (en) * 2023-01-20 2024-07-25 Duke University Epitope-scaffold immunogens for pancoronavirus vaccines
WO2024210175A1 (ja) * 2023-04-07 2024-10-10 国立大学法人大阪大学 濾胞性ヘルパーT細胞誘導性SARS-CoV-2スパイクタンパク質の部分ペプチド
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof
CN119143850A (zh) * 2024-08-20 2024-12-17 复旦大学 广谱抑制流感病毒的多肽及在预防和/或治疗流感病毒感染中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531204T3 (es) 2003-02-25 2015-03-11 Vaccibody As Anticuerpo modificado
JP2013532971A (ja) * 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
BR112014015016B1 (pt) 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
IL260030B2 (en) * 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2020176797A1 (en) 2019-02-27 2020-09-03 Nektar Therapeutics Immunotherapeutic combination for treating cancer
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
WO2021216954A1 (en) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions and methods for treating or preventing virus infection

Also Published As

Publication number Publication date
AU2021262521A1 (en) 2022-12-08
CA3176527A1 (en) 2021-11-04
IL297621A (en) 2022-12-01
WO2021219897A1 (en) 2021-11-04
CN116096735A (zh) 2023-05-09
BR112022021905A2 (pt) 2022-12-13
JP2023524054A (ja) 2023-06-08
MX2022013661A (es) 2022-11-30
US20230165952A1 (en) 2023-06-01
EP4143210A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
KR20230005962A (ko) 베타코로나바이러스 예방 및 치료요법
US12516116B2 (en) Homodimeric protein constructs
KR102713707B1 (ko) 신규 다가 나노입자 기반 백신
US20220089652A1 (en) Stabilized soluble pre-fusion rsv f proteins
US20250109175A1 (en) Recombinant gp120 protein with v1-loop deletion
US20220054625A1 (en) Immunogenic composition
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
CN118076646A (zh) 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用
US20250339509A1 (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
US12226476B2 (en) Helper epitope peptide and application thereof
RU2848314C1 (ru) Профилактика и лечение бетакоронавируса
CN118119646A (zh) 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用
CN121574211A (zh) 一种新型冠状病毒重组亚单位抗原及其制备方法和在疫苗中的应用
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法
BR112016007868B1 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240502

Comment text: Request for Examination of Application